Australia restricts use of cough and cold medicines in children; new labelling required from 1 Sept
This article was originally published in SRA
Executive Summary
Drug sponsors marketing cough and cold medicines in Australia will have to start amending their labelling and packaging from 1 September onwards to state that such products should not be given to children below six years of age1. Labels will also have to reflect that for children aged six to 11 years, these medicines should only be allowed on the advice of a doctor, pharmacist or nurse practitioner.
You may also be interested in...
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.